Induction of protective immunity against MHC class I-deficient, HPV16-associated tumours with peptide and dendritic cell-based vaccines

0346747 - ÚMG 2011 RIV GR eng J - Journal Article
Reiniš, Milan - Štěpánek, Ivan - Šímová, Jana - Bieblová, Jana - Přibylová, Hana - Indrová, Marie - Bubeník, Jan
Induction of protective immunity against MHC class I-deficient, HPV16-associated tumours with peptide and dendritic cell-based vaccines.
International Journal of Oncology. Roč. 36, č. 3 (2010), s. 545-551. ISSN 1019-6439. E-ISSN 1791-2423
R&D Projects: GA AV ČR IAA500520605; GA AV ČR IAA500520807
EU Projects: European Commission(XE) 18933 - CLINIGENE
Institutional research plan: CEZ:AV0Z50520514
Keywords : MHC class I-deficient tumours * CpG oligodeoxynucleotides * human papilloma virus
Subject RIV: EB - Genetics ; Molecular Biology
Impact factor: 2.571, year: 2010

We investigated the efficacy of peptide and peptide-pulsed dendritic cell-based vaccines in a murine model of experimental MHC class I-deficient tumours (TC-1/A9), expressing E6/E7 oncogenes derived from HPV16. Peptide vaccine based on the “short” peptide E749-57 harbouring the CTL epitope and co-administered to the C57BL/6 mice with CpG oligodeoxynucleotide as adjuvant effective against MHC class I-positive but not –deficient tumours, while the “longer” peptide E744-62 (harbouring CTL and Th epitopes)-based vaccines were effective against MHC class I-deficient tumours. Further, we investigated the efficacy of dendritic cells pulsed with either E749-57 or E744-62 peptides. Treatment with dendritic cells pulsed with a “short” peptide resulted in the tumour growth inhibition, albeit weaker as compared to the immunisation with the longer peptide-containing DC. Our data demonstrate that cell-based vaccines can be designed to elicit immunity against MHC class I-deficient tumours.
Permanent Link: http://hdl.handle.net/11104/0187685